Norda ASA
Norda ASA is a biotechnology company focused on healthcare diagnostics, primarily generating revenue through the development and commercialization of diagnostic solutions.
Business. Norda ASA (NORD.NFF) is a company operating within the Industrial Support Services industry. The firm is headquartered in Norway and is listed on the Oslo Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ2 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Norda ASA (NORD.NFF) is a company operating within the Industrial Support Services industry. The firm is headquartered in Norway and is listed on the Oslo Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Norda ASA operates with a capital structure that is heavily leveraged, as evidenced by a debt-to-equity ratio of 1.83, indicating that liabilities significantly exceed equity. The company's liquidity position is moderate, with a current ratio of 1.24, suggesting it can cover short-term obligations but with limited buffer. Cash and equivalents amount to 2,904,000 NOK, which is insufficient to cover the long-term debt of 16,172,000 NOK, resulting in a negative net cash position.
Profitability is a major concern for Norda, as it reported a net loss of 7,596,000 NOK, with a return on equity of -0.8599. This indicates that the company is not generating returns for its shareholders and is underperforming relative to industry norms. The operating loss of 1,619,000 NOK further highlights the company's inability to achieve operational profitability.
The company's revenue is not segmented by product or geographic region in the available data, making it difficult to assess the concentration of risk in specific markets or product lines. However, the lack of geographic diversification could pose a risk if the company's primary market experiences economic or regulatory challenges.
Norda's growth trajectory is uncertain, as the company has not provided specific revenue growth projections for the current or next fiscal year. The absence of capital expenditures and the continued operating cash outflow of 6,153,000 NOK suggest that the company is not investing in future growth and is instead relying on existing resources to sustain operations.
The risk assessment indicates a medium liquidity risk, primarily due to the company's negative net cash position and high debt levels. While the dilution risk is currently low, the company's financial position could deteriorate if it needs to raise additional capital through equity issuance. The risk of dilution is further compounded by the company's negative net income and operating cash flow, which may necessitate future financing.
Recent financial filings and transcripts do not provide specific details on strategic initiatives or new product launches. The company's focus appears to be on managing its existing financial obligations and maintaining operations in a competitive healthcare diagnostics market.
- Norda ASA is operating at a significant net loss, with a return on equity of -0.8599, indicating poor shareholder returns.
- The company's debt-to-equity ratio of 1.83 suggests a high level of financial leverage, increasing its financial risk.
- Norda has a negative net cash position, with cash and equivalents insufficient to cover long-term debt.
- The company is not investing in capital expenditures, which may hinder future growth.
- The risk of dilution is currently low, but the company's financial position could deteriorate if it needs to raise additional capital.
Bull / Bear case
Generated · model-assistedRevenue surged 327.8% year-over-year to NOK 371.9 million, indicating a significant recent operational turnaround.
Net income jumped 304.0% to NOK 125.9 million, demonstrating strong profitability recovery in the latest period.
Operating income increased 196.4% to NOK 161.5 million, highlighting improved core business efficiency and margins.
Cash conversion ratio of 0.81 exceeds the cohort median of 0.7, suggesting superior cash generation capabilities.
Dilution risk is assessed as low, providing some stability for existing shareholders regarding equity structure.
Net margin of -81.7% places the company in the bottom quartile of its industrial support services cohort.
Operating margin of -17.4% falls into the bottom quartile compared to peers, signaling persistent operational challenges.
Debt-to-equity ratio of 1.83 is significantly higher than the cohort median of 0.12, indicating high leverage.
Liquidity risk is rated as medium, suggesting potential difficulties in meeting short-term financial obligations.
In focus — financials by report
Revenue kr 46.0k; Operating income -kr 1.1M.
- ▍Revenue kr 46.0k
- ▍Operating income -kr 1.1M
- ▍Net margin -5897.8%
Revenue kr 0.00; Operating income -kr 1.0M.
- ▍Revenue kr 0.00
- ▍Operating income -kr 1.0M
Revenue kr 89.0k; Operating income -kr 3.4M.
- ▍Revenue kr 89.0k
- ▍Operating income -kr 3.4M
- ▍Net margin 23102.2%
Revenue kr 93.0k; Operating income -kr 1.6M.
- ▍Revenue kr 93.0k
- ▍Operating income -kr 1.6M
- ▍Net margin -8167.7%
Revenue kr 86.9M, −32,1% YoY; Operating income −49,7% YoY.
- ▍Revenue kr 86.9M, −32,1% YoY
- ▍Operating income −49,7% YoY
- ▍Net income −68,9% YoY
- ▍Net margin 35.9%
Revenue kr 128.0M, −8,1% YoY; Operating income +25,1% YoY.
- ▍Revenue kr 128.0M, −8,1% YoY
- ▍Operating income +25,1% YoY
- ▍Net income +22,0% YoY
- ▍Net margin 78.3%
Revenue kr 139.3M, −70,3% YoY; Operating income −80,5% YoY.
- ▍Revenue kr 139.3M, −70,3% YoY
- ▍Operating income −80,5% YoY
- ▍Net income −80,8% YoY
- ▍Net margin 59.0%
Revenue kr 469.1M; Operating income kr 445.5M.
- ▍Revenue kr 469.1M
- ▍Operating income kr 445.5M
- ▍Net margin 91.2%
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Norda ASA Market data — financials · 2026-05-28
Ownership & reference
Leadership
- Hilde Slemdal LeinaasCEO
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Operating cash flow (annual): USD -4.32MUnknown
- Total operating expenses (annual): USD 4.37MUnknown
- R&D expense (annual): USD 1.61MUnknown
- Net income (annual): USD -4MUnknown
- Capex (annual): USD 17.75KUnknown
- Operating income (annual): USD -4.37MUnknown
- EPS (diluted) (annual): USD-PER-SHARES -0Unknown
- EPS (basic) (annual): USD-PER-SHARES -0Unknown
- Pre-tax income (annual): USD -4.05MUnknown
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 10.1%Derived (calculated)
- Current ratio (FY 2025-12-31): 0.71xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.17xDerived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 27.0%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 1,149.5%Derived (calculated)
- Shareholders' equity (annual): USD 64.77MSEC XBRL filing
- Current liabilities (annual): USD 902.37KSEC XBRL filing
- Total liabilities (annual): USD 11.11MSEC XBRL filing
- Current assets (annual): USD 644.25KSEC XBRL filing
- Shares outstanding (annual): 18.88MSEC XBRL filing
- Total assets (annual): USD 75.86MSEC XBRL filing
- Operating income (YoY) (2025-03-31 vs 2024-03-31): -849.1%Derived (calculated)
- EPS (basic) (YoY) (2025-03-31 vs 2024-03-31): -10.3%Derived (calculated)
- EPS (diluted) (YoY) (2025-03-31 vs 2024-03-31): -10.3%Derived (calculated)
- Revenue (YoY) (2025-03-31 vs 2024-03-31): 100.0%Derived (calculated)